Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.
Mol Ther
; 24(8): 1470-7, 2016 Aug.
Article
en En
| MEDLINE
| ID: mdl-27109630
ABSTRACT
Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups 2-6 years old in The Gambia; 5-17 months old in Burkina Faso; 5-12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Virus Vaccinia
/
Adenovirus de los Simios
/
Vacunas contra la Malaria
/
Vectores Genéticos
/
Malaria
/
Epítopos
Límite:
Animals
/
Child
/
Child, preschool
/
Humans
/
Infant
/
Newborn
País como asunto:
Africa
Idioma:
En
Año:
2016
Tipo del documento:
Article